Distribution of Different Clinical Forms of Hepatitis B Virus (HBV) Infection among HBV Infected Patients Referred to Al-Zahra Hospital, Isfahan, Iran

Document Type : Original Research

Authors
Department of Biology, Islamshahr Branch, Islamic Azad University, Islamshahr, Iran
Abstract
Aims: Despite the vast global vaccination programs against the HBV infection, millions of people are chronic HBV carriers worldwide. The present study aimed to evaluate the distribution of different clinical forms of Hepatitis B infection among HBV infected patients to find the frequency of people at risk of developed liver diseases in Isfahan province.

Materials & Methods: This cross-sectional study was performed on 600 HBV infected patients admitted to Al-Zahra hospital in Isfahan from March 2017 to March 2018. Based on the virological markers, HBV infection in participants was categorized into four clinical forms including post-infection immunity, acute hepatitis, asymptomatic carrier state, and chronic active hepatitis. Enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) were used for screening HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe, and viral DNA in serum samples.

Findings: In this study, 308 (51.3%) females and 292 (47.7%) males with HBV infection and the mean age of 39 years were participated, of whom 189 (31.5%), 172 (28.7%), 138 (23%), and 101 (16.8%) participants were found to be in the post-infection immunity, acute hepatitis, asymptomatic carrier state (inactive carrier), and chronic active hepatitis forms of HBV infection, respectively.

Conclusion: The results of this study highlighted the high prevalence of asymptomatic carrier and chronic active hepatitis forms of HBV infection in 20-40 year old patients. Extensive measurements are needed to determine the prevalence of these two mentioned forms of HBV infection in all provinces of Iran in order to control the economic and life burden of disease in people not covered by the infant vaccination programs in Iran.

Keywords


1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014; 384 (9959): 2053-63.
2. Auta A, Adewuyi EO, Kureh GT, Onoviran N, Adeloye D. Hepatitis B vaccination coverage among health-care workers in Africa: A systematic review and meta-analysis. Vaccine 2018; 36(32): 4851-60.
3. Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995; 20(4): 992-1000.
4. Pita I, Horta-Vale AM, Cardoso H, Macedo G. Hepatitis B inactive carriers: An overlooked population? GE Port J Gastroenterol 2014; 21(6): 241-9.
5. Ott J, Stevens G, Groeger J, Wiersma S. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212-9.
6. David O. White, Frank J. Fenner. Medical Virology 4th ed. Academic Press an Imprint of Elsevier. 1994; pp: 359-379.
7. Kao J-H. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroent 2008; 2(4): 553-62.
8. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 19; 57(8): 1-20.
9. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28(1): 112-25.
10. Salehi-Vaziri M, Sadeghi F, Hashiani AA, Fesharaki MG, Alavian SM. Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepat Mon 2016; 16(4): e35577
11. Lusida MI, Nugrahaputra VE, Handajani R, Nagano-Fujii M, Sasayama M, Utsumi T, et al. Novel subgenotypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J Clin Microbiol 2008; 46(7): 2160-6.
12. Almasi-Hashiani A, Ayubi E, Mansori K, Salehi-Vaziri M, Moradi Y, Gholamaliei B, et al. Prevalence of hepatitis B virus infection among Iranian high risk groups: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench 2018; 11(2): 91-100.
13. Ozer A, Yakupogullari Y, Beytur A, Beytur L, Koroglu M. Risk factors of hepatitis B virus infection in Turkey: A population-based, case-control study: Risk Factors for HBV Infection. Hepat Mon 2011; 11(4): 263-8.
14. Ansari-Moghaddam A, Ostovaneh MR, Mood BS, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study. Hepat Mon 2012; 12(9): e6618.
15. Ghadir MR, Belbasi M, Heidari A, Jandagh M, Ahmadi I, Habibinejad H, et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon 2012; 12(2): 112-7.
16. Alavian SM. Hepatitis B is a Serious Health Problem in Some Parts of Iran; Sistan and Baluchestan Province. Int J Infect 2015; 2(2): e17937.
17. Rezaee R, Aghcheli B, Poortahmasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI): a systematic review and meta-analysis study. Hepat Mon 2015;15(5): e23618.
18. Saffar H, Ajami A, Saffar MJ, Shojaei J, Sotudeh-Anvari M, Shams-Esfandabad K, et al. Prevalence of hepatitis B virus seromarkers in young adults vaccinated at birth; impact on the epidemiology of hepatitis B infection in Iran. Hepat Mon 2014; 14(5): e17263.
19. Najafi F, Sayehmiri K, Najafi R. Efficacy of Hepatitis B Vaccination in Under Five-Year-Old Children in Iran: A Systematic Review and Meta-Analysis Study. Hepat Mon 2018; 18(6): e65385.
20. Karajibani M, Roushan MRH, Bayani M, Javanian M, Masrour-Roudsari J. Spontaneous relapse in patients with inactive chronic hepatitis B virus infection. Cas J Int Med 2018; 9(4): 393-6.
21. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007;11(4):945-63.
22. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol 2010; 58(4): 258-66.
23. Isogawa M1, Tanaka Y. Immunobiology of hepatitis B virus infection. Hepatol Res. 2015; 45 (2):179-89.
24. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138(5): 1747-54.
25. Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018; 68(3):526–549.